Skip to content

Comparison of Calcium Phosphate Cement With Patient-specific Implants for Cranial Reconstruction

Comparison of Calcium Phosphate Cement With Patient-specific Implants for Cranial Reconstruction: a Randomized-controlled Trial

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03841643
Acronym
CRAN-PSI
Enrollment
20
Registered
2019-02-15
Start date
2017-06-21
Completion date
2018-12-31
Last updated
2019-06-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cranial Defect

Keywords

cranial reconstruction, cement, patient-specific implant, preprothetic surgery, atrophic jaw

Brief summary

Background Cranial reconstruction after monocortical bonegraft harvesting remains a clinical challenge for the maxillofacial surgeon. At present, there is no gold standard technique advised. Patient-specific implants are gaining terrain in the field of craniofacial reconstruction. Comparative studies on differences in success rates between different biomaterials for application in craniofacial surgery are lacking. Aims The primary objective is to evaluate, in terms of cosmetic result, the postoperative successful outcome of patient-standardized implants for cranial reconstruction after bonegraft harvesting for jaw augmentation of patients with severely atrophic jaw. Design Patients considered eligible for cranial bone-augmentation of the severely atrophic jaw, that provide their consent for participation in the trial, will be randomized at recruitment into either the patient-specific implant (P) or cement (C) group. In the P group, the cranial bone defect will be reconstructed with a patient-specific implant (KLS Martin, Tuttlingen, Germany). In the C group, the cranial bone defect will be reconstructed with HydrosetTM (Stryker, New Jersey, USA), calcium phosphate cement, according to the current standard practice at the department. Parameters representing ease of application of the biomaterial , postoperative complication rate, cosmetic and functional outcome will be measured at fixed time-points during surgery and postoperative follow-up. A cone-beam computed tomography (CBCT) scan of both the donor (cranium) and receptor site (jaw) will be taken preoperatively, within 10 days postop, and 6 months post-operatively to measure biomaterial positioning. Conclusions Systematic reviews demonstrate the need for randomized prospective studies regarding implantable biomaterials used in facial reconstructive surgery. We hypothesize that patient-specific implants provide more user-friendly alternatives to the standard care, with better cosmetic results.

Interventions

DEVICEpatient-specific implant

solid titanium implant that functions as a guiding template for harvesting, and as an implant for reconstruction of the cranial defect

DEVICEcement

norian cement for reconstruction of the cranial defect

Sponsors

AZ Sint-Jan AV
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Caregiver)

Masking description

single-blind

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* patients aged 18 years or older * patients of all genders * patients with moderate to extreme bone atrophy of the jaw, caused by periodontitis or edentulism * patients requiring a full reconstruction (both anterior and posterior region) * patients receiving their surgery and follow-up care at the AZ Sint-Jan Brugge-Oostende AV * patients providing written informed consent

Exclusion criteria

* \- Patients not eligible according to abovementioned criteria * Patients with severe uncontrolled diabetes * Patients with contraindications for general anesthesia * Patients with known allergies to the biomaterials used * Patients with cranial vault without diploe and/or cranial vault thickness \<3mm, as defined with cone-beam CT * Patients with previous surgery of the skull region * Patients with an explicit risk of bleeding from cranial venous structures, as described by the radiologist based on his/her evaluation of the preoperative CBCT

Design outcomes

Primary

MeasureTime frame
volumetric measurement of cranial defect, through superimposition of the preoperative and postoperative cone beam computed tomographywithin 10 days postoperative

Secondary

MeasureTime frame
ease of application of both biomaterials, as graded with a 0 to 10 VAS score by the treating physicianperioperative
ease of application of both biomaterials, as determined by surgical time requiredperioperative
postoperative complications, as graded by CTCAE 4.0 by the treating surgeonwithin 30 days postoperative
patient satisfaction, as graded with a 0 to 10 VAS scorewithin 30 days postop
final implant position, as determined with CBCTat 6 months postop

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026